Literature DB >> 18136181

The use of estrogens and androgens in advanced mammary cancer; clinical and laboratory study of 105 female patients.

F E ADAIR, R C MELLORS.   

Abstract

Entities:  

Keywords:  ANDROGENS/therapy; BREAST/cancer; ESTROGENS/therapy

Mesh：

Substances：

Year:  1949        PMID： 18136181     DOI： 10.1001/jama.1949.02900500001001

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN： 0002-9955


× No keyword cloud information.
  6 in total

1.  General medical aspects of malignant disease.

Authors:  J Q MATTHIAS
Journal:  Postgrad Med J       Date:  1961-06       Impact factor: 2.401

2.  Biphasic actions of estrogen on colon cancer cell growth: possible mediation by high- and low-affinity estrogen binding sites.

Authors:  X Xu; M L Thomas
Journal:  Endocrine       Date:  1995-09       Impact factor: 3.633

3.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity.

Authors:  D E Wazer; M Joyce; G Solares; R Schmidt-Ullrich
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

5.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat.

Authors:  S Li; X Yan; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1994-02       Impact factor: 4.872
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.